CN114765955B - 用铁转运蛋白抑制剂(vit-2763)治疗镰状细胞病的方法和组合物 - Google Patents

用铁转运蛋白抑制剂(vit-2763)治疗镰状细胞病的方法和组合物 Download PDF

Info

Publication number
CN114765955B
CN114765955B CN202080074094.0A CN202080074094A CN114765955B CN 114765955 B CN114765955 B CN 114765955B CN 202080074094 A CN202080074094 A CN 202080074094A CN 114765955 B CN114765955 B CN 114765955B
Authority
CN
China
Prior art keywords
compound
group
scd
iron
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080074094.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114765955A (zh
Inventor
瓦尼亚·马诺洛娃
弗朗茨·杜伦伯格
娜娅·尼芬格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of CN114765955A publication Critical patent/CN114765955A/zh
Application granted granted Critical
Publication of CN114765955B publication Critical patent/CN114765955B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN202080074094.0A 2019-10-22 2020-10-22 用铁转运蛋白抑制剂(vit-2763)治疗镰状细胞病的方法和组合物 Active CN114765955B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
EP19000483.8 2019-10-22
US62/924,556 2019-10-22
EP20163777 2020-03-17
EP20163777.4 2020-03-17
EP20176336.4 2020-05-25
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (2)

Publication Number Publication Date
CN114765955A CN114765955A (zh) 2022-07-19
CN114765955B true CN114765955B (zh) 2025-06-24

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074094.0A Active CN114765955B (zh) 2019-10-22 2020-10-22 用铁转运蛋白抑制剂(vit-2763)治疗镰状细胞病的方法和组合物

Country Status (11)

Country Link
US (1) US20220274973A1 (https=)
EP (1) EP4048262A1 (https=)
JP (1) JP7594004B2 (https=)
KR (1) KR20220086563A (https=)
CN (1) CN114765955B (https=)
AU (1) AU2020369137A1 (https=)
BR (1) BR112022007616A2 (https=)
CA (1) CA3154524A1 (https=)
IL (1) IL291137A (https=)
MX (1) MX2022004806A (https=)
WO (1) WO2021078889A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025535398A (ja) 2022-10-21 2025-10-24 ビフォー （インターナショナル） エージー 二環式フェロポーチン阻害剤
EP4731218A1 (en) 2023-06-26 2026-04-29 Vifor (International) AG Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018192973A1 (en) * 2017-04-18 2018-10-25 Vifor (International) Ag Ferroportin-inhibitor salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002416C (en) 2015-10-23 2023-10-24 Vifor (International) Ag Benzimidazolyl derivatives for use as ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018192973A1 (en) * 2017-04-18 2018-10-25 Vifor (International) Ag Ferroportin-inhibitor salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The oral ferroportin inhibitor VIT-2763prevents hemolysis and vaso-occlusion in a sickle cell diseases model II;MANOLOVA Vania, et al;LIPPINCOTT WILLIAMS AND WILKINSNLD;20200612;第4卷;no. Supplement 1 *

Also Published As

Publication number Publication date
JP2023500060A (ja) 2023-01-04
CA3154524A1 (en) 2021-04-21
IL291137A (en) 2022-05-01
US20220274973A1 (en) 2022-09-01
JP7594004B2 (ja) 2024-12-03
WO2021078889A1 (en) 2021-04-29
KR20220086563A (ko) 2022-06-23
AU2020369137A1 (en) 2022-04-07
EP4048262A1 (en) 2022-08-31
MX2022004806A (es) 2022-05-16
BR112022007616A2 (pt) 2022-07-12
CN114765955A (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
CN114765955B (zh) 用铁转运蛋白抑制剂(vit-2763)治疗镰状细胞病的方法和组合物
Paesano et al. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women
JP7554253B2 (ja) 輸血依存性β－サラセミア（ＴＤＴ）の治療で使用するためのフェロポーチン阻害剤
JP7561180B2 (ja) 腎臓損傷の予防及び治療で使用するためのフェロポーチン阻害剤
KR20230134476A (ko) 골수이형성 증후군(mds)의 치료에 사용하기 위한 페로포틴-억제제
KR100350761B1 (ko) 에리트로포이에틴및철제제를함유하는약제학적조합제제
US20140350097A1 (en) Treatment of hypotension associated with hemodialysis
EA048997B1 (ru) Способы и композиции для лечения серповидно-клеточной болезни ингибитором ферропортина (vit-2763)
CN116710091A (zh) 用于治疗骨髓增生异常综合征(mds)的膜铁转运蛋白抑制剂
EP2560644B1 (en) A pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent
Mueller et al. Prevention of red cell dehydration: a possible new treatment for sickle cell disease
EA048075B1 (ru) Ингибиторы ферропортина для применения при лечении трансфузионно-зависимой бета-талассемии (tdt)
EA049341B1 (ru) Применение ингибиторов ферропортина для лечения миелодиспластических синдромов (мдс)
EA047958B1 (ru) Ингибиторы ферропортина для применения с целью предупреждения и лечения повреждений почек
KR20260028017A (ko) 유전성 혈색소침착증(hh)의 치료에 사용하기 위한 페로포틴-저해제
Vet—QV03AC01 Adverse Effects and Precautions
British Nutrition Foundation Iron and Anaemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant